How to Cite
Abstract
The study included 160 patients with advanced ovarian cancer (OC) who underwent combined treatment from January 2000 to January 2013 at the N.N. Petrov Research Institute of Oncology. Compared to non-mutated patients, BRCA-positive patients were characterized by a longer platinum-free interval (BFI) (14 months [95% CI 9.6-36.4 months] versus 8 months [95% Ci 4.8-12.4 months]; P = 0.006), with the largest median of the BFI were established using the CAP scheme - 33.5 months versus 12 months using the TCbP scheme. Half of patients with a mutation in the BRCA1 gene (20/40 (50%)) had an isolated recurrence in the pelvic area versus 35/120 (29.2%) of patients without mutations (p = 0.00001). The progression of distant foci in the first recurrence of the disease in patients with mutations was significantly lower (15/40 (37.5%) versus 84/120 (70%), p = 0.00001). In addition 85% of recurrences in BRCA-positive patients were platinum-sensitive. Only the age of patients with advanced OC was an independent prognostic factor of BFI since the start of treatment (p = 0.00001).References
Максимов С.Я., Имянитов Е.Н., Гусейнов К.Д., Городнова ТВ. Клинические особенности BRCA-позитивного рака яичников//Сибирский онкологический журнал. -2013. -№ 6. -С. 14-19.
Соколенко А.П., Иевлева А.Г, Митюшкина Н.В. и др. Синдром наследственного рака молочной железы и яичников в Российской Федерации//Acta naturae. -2010. -№ 4. -С. 35-39.
Boyd J., Sonoda Y, Federici M.G. et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer//JAMA. -2000. -Vol. 17. -Р. 2260-2265.
Friedlander M., Trimble E., Tinker A. Gynecologic Cancer Inter Group. Clinical trials in recurrent ovarian cancer//Int. J. Gynecol. Cancer. -2011. -Vol. 21. -Р. 771-775.
Ferlay J. et al. GLOBOCAN 2012 v1.0/Cancer Incidence and Mortality Worldwide: IARC CancerBase. -2013. -Vol. 11. -Р 278.
Gorodnova T.V., Sokolenko A.P., Ivantsov A.O. et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation//Cancer Lett. -2015. -Vol. 2. -P. 363-367.
Gore M.E., Atkinson R.J., Thomas H. et al. A phase II trial of ZD0473 in platinum-pretreated ovarian cancer//Eur. J. Cancer. -2002. -Vol. 18. -Р 2416-2420.
Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world//J. Clin. Oncol. -2006. -Vol. 24. -№ 14. -Р 2137-2150.
Markman M. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population//Gynecol Oncol. -2012. -Vol. 1. -Р 278-279.
Recurrent Ovarian Cancer Ovarian Cancer National Alliance Conference Sarah Adams, MD July 25. -2015.
Suspitsin E.N., Sherina N.Y, Ponomariova D.N. et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients//Hereditary Cancer in Clinical Practice. -2009. -Vol. 10. -P. 86 -97.
Tan D.S., Rothermundt C., Thomas K. et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2//J. Clin. Oncol. -2008. -Vol. 97(9). -P. 2187-959.
Tutt A., Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition//Trends Mol Med. -2002. -Vol. 12. -Р 571-572.
Yoshida K, Miki Y Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage//Cancer Sci. -2004. -Vol. 11. -Р 866-871.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017